17 Jan 2023 Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study Investors | Therapeutics
19 Dec 2022 Avacta to Host Therapeutics Division Science Day on 23rd February 2023 Investors | Therapeutics
05 Sep 2022 AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration Investors | Therapeutics
01 Sep 2022 Phase I clinical study of AVA6000 to advance to the fourth cohort Investors | Therapeutics
29 Jun 2022 Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin Investors | Therapeutics
16 May 2022 AffyXell expands its strategic partnership with GenScript ProBio Investors | Therapeutics
11 May 2022 Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus Investors | Therapeutics